Matthew Koss
8Patents
3h-index
12Co-inventors
50Inventor score
Filing activity: Apr 15, 2014 → Dec 17, 2024
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10023916B2 | Markers of tumor cell response to anti-cancer therapy | Chemistry; Metallurgy | 5 | Active |
| US11781131B2 | CRISPR/Cas dropout screening platform to reveal genetic vulnerabilities associated with tau aggregation | Physics | 4 | Active |
| US11845931B2 | CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation | Physics | 4 | Active |
| US11845957B2 | Models of tauopathy | Chemistry; Metallurgy | 2 | Active |
| US12110502B2 | Models of tauopathy | Chemistry; Metallurgy | 1 | Active |
| US12209238B2 | CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation | Physics | 1 | Active |
| US12421512B2 | CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation | Physics | 0 | Active |
| US12391920B2 | Models of tauopathy | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.